ConductScience.org, home

Paper37477752

Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.

Ohyama R and 4 others. Clin Exp Nephrol, 2023. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study. Papers, record 37477752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37477752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
PubMed
Journal
Clin Exp Nephrol
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
2.16
iCite
Revised in PubMed
2026-10-31
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ohyama RRie
2Fujinaga SShuichirohttps://orcid.org/0000-0002-2957-3705
3Sakuraya KKoji
4Hirano DDaishi
5Ito SShuichi

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Nephrotic SyndromeMajor topic
Child
Humans
Adolescent
Rituximab
Retrospective Studies
Treatment Outcome
Immunosuppressive Agents
Recurrence
Remission Induction

Source PubMed

Download CSV of topics

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12857421Long-term outcome for children with minimal-change nephrotic syndrome.Lancet1985https://conductscience.org/library/papers/2857421PubMed
235286456Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.Pediatr Nephrol2022https://conductscience.org/library/papers/35286456PubMed
332232637Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study.Pediatr Nephrol2020https://conductscience.org/library/papers/32232637PubMed
431874801Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes.Kidney Int2020https://conductscience.org/library/papers/31874801PubMed
523739238Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.Kidney Int2013https://conductscience.org/library/papers/23739238PubMed
629913001Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.JAMA Pediatr2018https://conductscience.org/library/papers/29913001PubMed
735154548
Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life.
Arch Med Sci2022https://conductscience.org/library/papers/35154548PubMed
825085238Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature.Nephrol Dial Transplant2015https://conductscience.org/library/papers/25085238PubMed
933786660Oral cyclophosphamide therapy in 100 children with steroid-sensitive nephrotic syndrome: experience from a developing country.Pediatr Nephrol2021https://conductscience.org/library/papers/33786660PubMed
1030887110Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome.Pediatr Nephrol2019https://conductscience.org/library/papers/30887110PubMed
1118465150Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.Pediatr Nephrol2008https://conductscience.org/library/papers/18465150PubMed
1225277597Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial.Pediatr Nephrol2015https://conductscience.org/library/papers/25277597PubMed
1323271494Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.Eur J Pediatr2013https://conductscience.org/library/papers/23271494PubMed
1436071552Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.Nephrol Dial Transplant2023https://conductscience.org/library/papers/36071552PubMed
1520049616Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.Pediatr Nephrol2010https://conductscience.org/library/papers/20049616PubMed
1621394465Cyclophosphamide in steroid-dependent nephrotic syndrome.Pediatr Nephrol2011https://conductscience.org/library/papers/21394465PubMed
1716126050Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome.J Pediatr2005https://conductscience.org/library/papers/16126050PubMed
1835354600Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.J Am Soc Nephrol2022https://conductscience.org/library/papers/35354600PubMed
1927558467Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.Clin Exp Nephrol2017https://conductscience.org/library/papers/27558467PubMed
2032337638Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome.Pediatr Nephrol2020https://conductscience.org/library/papers/32337638PubMed

See all 37 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42435047Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome.Pediatr Nephrol2026https://conductscience.org/library/papers/42435047PubMed
42305001[Efficacy and safety of rituximab in children with refractory nephrotic syndrome].Zhongguo Dang Dai Er Ke Za Zhi2026https://conductscience.org/library/papers/42305001PubMed
42014615When should sequential rituximab therapy for long-term B-cell depletion be initiated in children with steroid-sensitive nephrotic syndrome?Pediatr Nephrol2026https://conductscience.org/library/papers/42014615PubMed
41400699Optimal selection and timing of steroid-sparing therapy in childhood nephrotic syndrome: what determines long-term outcomes of adult survivors?Pediatr Nephrol2026https://conductscience.org/library/papers/41400699PubMed
41329290Comparison of efficacy of single-dose and double-dose rituximab in the treatment of refractory nephrotic syndrome in children: a retrospective study.Pediatr Nephrol2026https://conductscience.org/library/papers/41329290PubMed
41321785Identification of Risk Factors for Relapse following Rituximab Therapy in Children with Steroid-Sensitive Nephrotic Syndrome.Kidney Dis (Basel)2025https://conductscience.org/library/papers/41321785PubMed
39417849Response to Fujinaga - discontinuing immunosuppression in idiopathic nephrotic syndrome.Pediatr Nephrol2025https://conductscience.org/library/papers/39417849PubMed
38457032
Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab.
Clin Exp Nephrol2024https://conductscience.org/library/papers/38457032PubMed
38456917Pre-emptive rituximab administration for discontinuation of steroid-sparing agents in patients with complicated frequently-relapsing or steroid-dependent nephrotic syndrome.Pediatr Nephrol2024https://conductscience.org/library/papers/38456917PubMed
38010466Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial).Clin Exp Nephrol2024https://conductscience.org/library/papers/38010466PubMed
37864679Changes in adverse events after multiple rituximab courses in patients with complicated steroid-dependent nephrotic syndrome.Clin Exp Nephrol2024https://conductscience.org/library/papers/37864679PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37477752

GET https://conductscience.org/api/papers/v1/37477752/references?page=2